News

The trial showed statistical significance that the product provided pain relief after surgery in the treatment group using ELI-200 compared to the placebo group. The company said secondary

Results from the randomised, blinded study 201316 showed that umeclidinium 62.5mcg once daily achieved a statistically significant improvement in lung function measured by trough forced expiratory volume in

Until today’s orphan drug approval, no specific coagulation factor replacement therapy was available for patients with hereditary Factor X deficiency. In healthy individuals, the Factor X protein activates

As on June 30, 2015, Jubilant Life Sciences had a total of 815 filings for formulations of which 389 have been approved in various regions globally. This includes

Imperial has secured £3m in funding from the Wellcome Trust Seeding Drug Discovery program to build upon the research of professor Michael Schneider, the British Heart Foundation Simon

Praxbind is indicated for patients treated with Pradaxa® (dabigatran etexilate), when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures or in life-threatening or

The company has received an initial investment of $10 million, with an additional $15 million due upon the achievement of certain milestones. Proceeds from the Series B financing

The study was intended to see if a combination of ganetespib and docetaxel would work better than docetaxel alone for advanced non-small cell lung adenocarcinoma. Synta halted the

China-based Yabao will co-develop Lilly’s sodium-glucose linked transporter inhibitor (SGLT1) molecule. Under the deal, Yabao secures the rights to develop and commercialize the SGLT1 compound in China, while